LogicBio out-licenses LB-001 in Greater China; inks deal in Japan

27 April 2021
handshake

USA-based LogicBio Therapeutics (Nasdaq: LOGC) has announced a strategic collaboration and option agreement with China-based CANbridge Pharmaceuticals leveraging LogicBio’s gene editing and gene delivery platforms.

Under the agreement, LogicBio grants CANbridge and exclusive option to license in Greater China its investigational therapy LB-001, an in-vivo gene editing technology based on LogicBio's GeneRide platform for the potential treatment of methylmalonic acidemia (MMA).

The agreement also grants CANbridge a worldwide license for the adeno-associated virus (AAV) sL65, the first capsid produced from LogicBio's sAAVy platform, and development support on gene therapy candidates for the treatment of Fabry and Pompe disease plus two optional indications.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology